International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 1 | Views: 98 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Student Project | Cancer Science | India | Volume 11 Issue 7, July 2022 | Rating: 4.6 / 10

Dostarlimab in Cancer: Cure or a Buzz?

Rythm Walia

Abstract: Dostarlimab, a monoclonal body is now being used as an immunotherapy drug for treating cancer. A monoclonal body is a type of protein that is particularly produced in a laboratory to serve as substitute antibodies that can reinstate, amplify, alter, or imitate the immune systems strike on cells that are unwanted and harmful, such as cancer cells. Cancer being the second leading cause of deaths in the US; according to the recent reports, is now a major threat to the society especially to the urban groups. Among all the worst cases of cancer, endometrial cancer has been the most predictable type gynecologic malignancy in the advanced world. Endometrial Cancer (EC) has been assorted as microsatellite stable or microsatellite instability-high; upto 30% of all ECs are categorized as dMMR and MSI-H. Since the spotting of a molecular subclassification system for EC, experiments in immune checkpoint inhibitor therapies are trying to focus on evident subgroups prognostic for response, specifically microsatellite instability-hypermutated or DNA mismatch repair-deficient EC. This review outlines existing data on Dostarlimab and explains if it is really a cure or a buzz.

Keywords: Dostarlimab, monoclonal bodies, endometrial cancer, dMMR, MSI-H

Edition: Volume 11 Issue 7, July 2022,

Pages: 1938 - 1940

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait